Site Number - 1631 — Yukon, Oklahoma

Site Number - 1631 is a clinical research site located in Yukon, Oklahoma, United States 73099.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Site Number - 1631 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Chronic Inflammatory Demyelinating Polyneuropathy.

Sponsors: Immunovant Sciences GmbH.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Yukon

Browse all research sites in Oklahoma · View every site in Yukon

• Integris Yukon Hospital
• Tekton Research
• Integris Family Care Yukon
• Research Site
• Tekton Research, Inc - Yukon Location
• Ironwood Investigational Site
• GSK Investigational Site
• Pfizer Investigational Site
• Tekton Research- Yukon
• Tekton Research - Oklahoma - Primary Health Partners
• Aquilo Research
• Santarus Clinical Investigational Site 5001

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site Number - 1631?

Site Number - 1631 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site Number - 1631 conducted?

Site Number - 1631 has 1 clinical trials on record, with 1 currently active. Their work covers Chronic Inflammatory Demyelinating Polyneuropathy.

Is Site Number - 1631 accredited by Crixeo Clinical Trials?

Site Number - 1631 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site Number - 1631?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.